Glioblastoma has a poor prognosis, with a 5-year survival rate of less than 10%.
1,2 Nearly all patients experience recurrence following standard-of-care surgical resection, radiotherapy, and temozolomide.
2-4 Treatment options at recurrence are limited, and no therapy has prolonged overall survival (OS) in this setting, which underscores the need for novel therapeutic interventions in this patient population.
4